Results Healthcare   |   Results International

Insights

We add value by understanding our sectors inside out, and release regular industry research and reports

MedNous: why pharma is paying a premium for assets

By Martin Gouldstone, Tim Sturgeon 13 Mar 2018

For pharma M&A, 2018 started with a bang. Almost $30 billion of acquisitions have been announced since the beginning of the year. This strong start has raised hopes of more deals to come as 2018 unfolds. However, seemingly sky-high valuations have left some people wondering whether ‘animal spirits’ have overcome rational heads and led to big pharma overpaying for top assets. Sanofi SA’s $11.6 billion offer for US haemophilia specialist Bioverativ Inc attracted attention for both the size of the deal and the premium paid..


To read ‘Why pharma is paying a premium for assets’ in full

 

Click here

 

Martin Gouldstone

Partner

Contact Martin

Tim Sturgeon

Associate

Contact Tim

Insights

Weekly Public Healthcare Sector Analysis, News, Blogs & White Papers

View our insights     SUBSCRIBE

Connect with us

Follow Results Healthcare on Twitter Follow Results Healthcare on LinkedIn

Your Nearest Office